Fluorination has gained an increasingly important role in drug discovery and development. Here we describe a versatile strategy that combines cytochrome P450-catalyzed oxygenation with deoxofluorination to achieve mono-and polyfluorination of non-reactive sites in a variety of organic scaffolds. This procedure was applied for the rapid identification of fluorinated drug derivatives with enhanced membrane permeability.Fluorination has become an increasingly important tool for fine-tuning the pharmacokinetic and pharmacological properties of drugs and lead compounds, leading to a growing number of fluorine-containing pharmaceuticals on the market. 1 Benefits of hydrogen-to-fluorine substitutions arise principally from their effects on membrane permeability, metabolic stability, and/or receptor-binding properties of bioactive molecules. 1-3 In many cases, fluorination of much less active precursors yielded potent drugs, with enhanced bioavailability, reduced toxicity, or improved affinity for the target receptor. 3 A number of methods have been developed for synthesis of fluorinated compounds, 4,5 including asymmetric fluorination strategies 6,7 and chemo-enzymatic approaches 8,9 . Despite this progress, selective incorporation of fluorine at non-activated or weakly-reactive sites of a target scaffold remains difficult and may require several synthetic steps.Here we describe a facile, two-step procedure for the selective fluorination of one or more nonactivated sites in an organic molecule. This approach couples the exceptional ability of cytochrome P450 monooxygenases to selectively insert oxygen into non-reactive C-H bonds with a deoxofluorination (DF) reaction in which the newly generated hydroxyl group is substituted by fluorine by means of a nucleophilic fluorinating reagent (Fig. 1). To test the validity of this approach, we targeted various classes of small molecules, including marketed pharmaceuticals (Supplementary Figure 1 online). For the enzymatic step, we used variants of the bacterial long-chain fatty acid hydroxylase P450 BM3 from Bacillus megaterium. Catalytic self-sufficiency, high monooxygenase activity, and high expression level in E. coli render P450 BM3 an attractive catalyst for in vitro and in vivo applications. 10 For this work, we assembled a panel of 96 P450s derived from a catalytically-promiscuous P450 BM3 variant identified in the early stages of the directed evolution of a proficient alkane monoxygenase. 11 These variants were found to exhibit good activity and various degrees of selectivity on alkanes and non-alkane substrates. 11The first group of test molecules (1, 2 and 3; Fig. 2a,b) contains a cyclopentenone moiety found in several natural products (e.g. jasmonoids, cyclopentanoid antibiotic, and prostaglandins). The synthesis and functionalization of these scaffolds is not trivial. 12 The activities of the enzymes towards these substrates were probed in multi-well format using GC and GC-MS (Fig. 2a). Depending on the substrate, approximately 30 to 50% of the 96 enzyme var...